Literature DB >> 12607724

Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade.

Olga Arbach1, Wolfgang L Gross, Angela Gause.   

Abstract

Churg-Strauss-Syndrome (CSS) often takes a mild course and is in many cases treated successfully by glucocorticosteroids (GC) alone. However, there are also several reports demonstrating the necessity of more intensive treatment in life threatening courses with cyclophosphamide and in less severe cases with other immunosuppressive or immunomodulatory drugs like azathioprine, methotrexate or interferon alpha. Relapses of the CSS are detected clinically and serologically and may require cyclophosphamide therapy as well as high-dose GC. We treated 3 cases between 2000 and 2001 that not only experienced a severe relapse (of the heart and the central nervous system) but also proved to be refractory to cyclophosphamide and GC therapy. In the absence of other options we decided to apply TNF-alpha blockers (etanercept in one case and remicade in the two other). This experimental treatment proved to be effective and safe and induced complete remission in one patient and partial remission in the second and at least stopped disease progression in the third. The BVAS 1 markedly improved after additional treatment with TNF-alpha blockers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12607724     DOI: 10.1078/0171-2985-00197

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  17 in total

1.  Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report.

Authors:  Erynn M Boyer; Martin Turman; Kathleen M O'Neil
Journal:  Pediatr Rheumatol Online J       Date:  2011-08-11       Impact factor: 3.054

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 3.  Pulmonary vasculitis.

Authors:  Kevin K Brown
Journal:  Proc Am Thorac Soc       Date:  2006

Review 4.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 5.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

Review 6.  Advances in the use of biologic agents for the treatment of systemic vasculitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

Review 7.  The utility of tumour necrosis factor blockade in orphan diseases.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 8.  Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Authors:  Loïc Raffray; Loïc Guillevin
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

9.  Etanercept prevents airway hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs.

Authors:  Zhenying Nie; David B Jacoby; Allison D Fryer
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 10.  Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Richard W Lee; David P D'Cruz
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.